RAP-219 Phase 2a Seizure Data and Planned Pivotal Trials Might Change The Case For Investing In Rapport Therapeutics (RAPP) [Yahoo! Finance]
Rapport Therapeutics, Inc. (RAPP)
Company Research
Source: Yahoo! Finance
Rapport Therapeutics recently presented new data and post hoc analyses from its Phase 2a trial of RAP-219 in drug-resistant focal onset seizures at the 2025 American Epilepsy Society Meeting, showing consistent clinical benefits, including reductions in seizure severity and improvements in patient-reported outcomes, alongside PET evidence of target engagement in key brain regions.
Show less
Read more
Impact Snapshot
Event Time:
RAPP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RAPP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RAPP alerts
High impacting Rapport Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RAPP
News
- Rapport Therapeutics (NASDAQ:RAPP) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=RAPP&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreMarketBeat
- Rapport Therapeutics (NASDAQ:RAPP) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Rapport Therapeutics (NASDAQ:RAPP) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $47.00 price target on the stock.MarketBeat
- Rapport Therapeutics (RAPP) Valuation Check After a 60% Year-to-Date Share Price Surge [Yahoo! Finance]Yahoo! Finance
- Rapport Therapeutics (NASDAQ:RAPP) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=RAPP&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StMarketBeat
RAPP
Earnings
- 11/6/25 - Beat
RAPP
Sec Filings
- 12/1/25 - Form 4
- 11/18/25 - Form 4
- 11/18/25 - Form 4
- RAPP's page on the SEC website